Delphi Ventures

Delphi Ventures, founded in 1988, is a venture capital firm based in San Mateo, California. The firm focuses primarily on life sciences, including biotechnology, medical devices, and healthcare IT. Over the years, Delphi Ventures has made significant contributions to the life sciences industry with over 318 investments and 190 exits. Notable investments by Delphi Ventures include Revance Therapeutics, Senseonics, and PTC Therapeutics. These companies have developed innovative solutions in neurotoxin aesthetics, continuous glucose monitoring, and treatments for rare diseases, respectively. Revance Therapeutics, for instance, is now a public company with significant revenue, reflecting Delphi Ventures' ability to identify and nurture high-potential startups. Delphi Ventures' investment strategy is centered on early and growth-stage investments, with a focus on supporting pioneering technologies and therapies. The firm has a strong track record of successful exits, including companies that have gone public such as EBR Systems and Senseonics, as well as several notable acquisitions like Seattle Genetics and Acclarent. The team at Delphi Ventures is led by experienced professionals such as Deepa Pakianathan, Douglas Roeder, and founder James Bochnowski. Their expertise and deep industry knowledge play a critical role in guiding portfolio companies toward successful growth and market leadership.